Press ReleasesView printer-friendly version << Back
Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors
“We are pleased to have Dr. McCamish join our board of directors. He brings Avadel tremendous experience as a senior executive overseeing research and development at several leading global companies, including Abbott,
Dr. McCamish is an internationally recognized expert in drug development and manufacturing. He is currently the President and Chief Executive Officer of
After earning a Ph.D. in Human Nutrition from
About Avadel Pharmaceuticals plc:
Cautionary Disclosure Regarding Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “believe,” “expect,” “look forward,” “on track,” “guidance,” “anticipate,” “estimate,” “project” and similar expressions, and the negatives thereof (if applicable).
Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks and as a result there can be no assurance that actual results of our research, development and commercialization activities and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include the risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended
Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise the forward-looking statements contained in this Annual Report.
Chief Financial Officer
Phone: (636) 449-1843
LifeSci Advisors, LLC
Phone: (212) 915.2564
Source: Avadel Pharmaceuticals plc